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http://www.diagnosticpathology.org/content/7/1/181RESEARCH Open AccessThe ectopic expression of BRCA1 is associated
with genesis, progression, and prognosis of
breast cancer in young patients
Qingli Zhang*, Qinghui Zhang, Hua Cong and Xiaoli ZhangAbstract
Objective: The study is to explore the histopathological features and the molecular marker expression of young
women with breast cancers.
Methods: The pathological data of 367 cases of female breast cancer patients were retrospectively analyzed,
focusing on the analysis of young breast cancer incidence trends and the clinical and pathological features.
Results: Compared with elderly breast cancer patients, young women with breast cancers had larger tumor sizes,
higher histological grades, and lymph node metastasis rates. The majority of patients were in the PTNM III stage,
with the clinical and pathological features of strong invasiveness. The positive expression rate of the BRCA1 protein
in the young group was higher than that in the old group. BRCA1 expression was positively correlated with the
PTNM stage and axillary lymph node metastasis (P < 0.05).
Conclusions: The ectopic expression of BRCA1 is associated with the genesis, progression, and prognosis of young
breast cancer patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1628000054838044
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Breast cancer has become one of the common diseases
that seriously threaten women health. From 1982 to
2001, female breast cancer incidence showed an increas-
ing trend in the Beijing urban area, with an average an-
nual increase of 4.6% to 4.9% [1]. The age of onset of
breast cancer in China is 8–10 years younger than in the
Europe and the United States [2]. Women younger than
35 year old are less likely to get breast cancer according
to clinical recordings. However, the incidence has an in-
creasing trend with the increase of overall breast cancer
patients in the recent years [2].
The breast cancer susceptibility gene (BRCA1), a tumor
suppressor gene, encoded a factor inhibiting cell growth.
The factor is also involved in cell cycle control, gene tran-
scription regulation, DNA damage repair, apoptosis, and
other important cellular processes. BRCA1 plays an* Correspondence: qinglizhang2012@163.com
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reproduction in any medium, provided the orimportant role in maintaining gene stability [3], with its
mutation being related with 35%-40% of familial breast
cancers and ovarian cancers. WWOX (WW domain
containing oxidoreductase) is a new gene identified by
Bednarek et al. using the shotgun gene sequencing techno-
logy combined with the separation and analysis of transcripts
corresponding to the region of interest [4]. The WWOX
gene is found with lost heterozygosity, abnormal transcrip-
tion and low protein expression level in various kinds of
tumors. The WWOX gene is considered to be a new tumor
suppressor gene after discovery of the FHITgene.
In this study, the expression of the breast cancer suscep-
tibility gene BRCA1 and the tumor suppressor gene
WWOX is detected using the immunohistochemical
method in young and old female breast cancer patients.
The mutation state of BRCA1 gene exon 2 and 20 was
detected by PCR amplification and the direct sequencing
testing method. The relationship between clinicopathologi-
cal parameters and their clinical significance was analyzed.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Materials
One hundred and eighty-one cases of patients (younger
than 35 years), who undergone surgical resection or
biopsy and confirmed by pathology to be breast cancer
patients, were collected from January 1998 to December
2007 (Figure 1). They were from 19 to 35 years old, and
the median age is 27 years old. One hundred and eighty-
six cases of elderly female breast cancer patients (≥ 60
years) were randomly selected from the same period.
They were from 60 to 85 years old, and the median age
is 73 years old. The two groups of pathological data were
analyzed retrospectively. Clinical and pathological char-
acteristics of pathologic types, tumor sizes, histological
grades, pathological stages, and lymph node metastasis
were comparable. Pathological diagnosis and histological
grades were determined using the World Health
Organization breast tumor diagnostic criteria (2003).
The UICC breast cancer pathological stage was deter-
mined using the pathological tumor-node-metastasis
(PTNM) staging standard (2006). Prior written and
informed consent was obtained from every patient and
the study was approved by the ethics review board of
Shandong University.
Immunohistochemical method
The WWOX antibody was purchased from Beijing
Boaosen Biotechnology Co., Ltd. BRCA1 antibody was
purchased from Wuhan Boster Biological Engineering
Co., Ltd. ER, PR, and Ki67 were expressed in the nu-
cleus. HER2 was expressed in the cell membrane.
BRCA1 was expressed in the nucleus or cytoplasm.
BRCA1 staining criteria was described as follows:
according to the expression of the area, < 5% of staining
was recorded as (−); 5~20% of staining was recorded as
(+); 21-50% of staining was recorded as (++); and > 50%
of staining was recorded as (+++). WWOX was
expressed in the cytoplasm. According to the expression
extent, tumor cells without staining was recorded as (−);
tumor cells with low staining was recorded as (+);Figure 1 Analysis of numbers of the female breast cancer case, includ
hospital in the past 10 years.medium staining was recorded as (+ +); and extensive
staining was recorded as (+ + +).
Genomic DNA Extraction and PCR Amplification
The Genomic DNA from breast cancer tissue was
extracted using the TIANamp Genomic DNA extraction




CCA AATTACACAGC) used in PCR amplification were
synthesized by Shanghai Biological Engineering Techno-
logy Co., Ltd (Shanghai, China).
DNA sequencing
DNAStar MagAlign analysis software was used for se-
quence comparisons. Single nucleotide polymorphism
(SNP) loci were searched. Data analysis of all the nucleic
acid sequence was carried out according to the wild-type
cDNA sequence of BRCA1 (U14680.1) in the GenBank.
Translation from nucleotide to protein was compared using
the Blast2 application program on the U.S. Center for Bio-
technology Information (NCBI) website to determine
whether the mutation sites will cause amino acid change.
Statistical analysis
The application program SPSS16.0 was used for statis-
tical analysis. Differences between the two groups were
compared using the χ2 test. P < 0.05 was considered sta-
tistically significant. The correlation between two va-
riables was determined using the Pearson parameter




Among the patients being investigated, there were 160 sin-
gle occurrence cases (88.4%) and 21 multiple occurrence
cases (11.6%) in the young women group. There were 179
single occurrence cases and 7 multiple occurrence casesing the young and older breast cancer cases, diagnosed in the
Table 2 Comparative analysis of the
immunohistochemical results of young and old patient
groups
Indicators Young group (%) Old group (%) X2 P value
BRCA1 53.206 0.001*
— 37 (34.6) 72 (64.3)
+ 13 (12.1) 30 (26.8)
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pathological tumor-node-metastasis (PTNM) staging
standard, tumor sizes were divided into the following
grades: tumor size smaller than or equal to 2 cm (T1),
tumor size larger than 2 cm, but smaller than or equal to
5 cm (T2), tumor size larger than 5cm (T3) (Table 1). Data
comparison showed that more patients with T3 tumor size
appeared in the young group than the older group. The
difference was statistically significant (P < 0.05) (Table 1).
The number of breast cancer cases, diagnosed in our
hospital, has significantly increased year by year between
1998 and 2007, with no significant changes in the case
numbers of the young patient group, but slight increases
in the case numbers of the older patient group (Figure 1).
In both of the two groups, invasive ductal carcinoma is
the most common histopathologic type, followed by
ductal carcinoma in situ and invasive lobular carcinoma.
Invasive ductal carcinoma was graded according to the
amount of duct formation in the tumor tissues, the sizes
of tumor cell atypia and the numbers of mitotic nucleus
by reference to the Elston and Eliis histological grading
criteria. It was found that patients in the younger group
have more grade III tumors than the older group. The
difference was statistically significant (P < 0.01)
(Table 1).Table 1 Comparative analysis of the clinicopathological
parameters in the young groups and old groups
Parameters Young (n %) Old (n %) x2 P
Tumor size 7.053 0.029 *
≤2 cm 64 (35.4) 81 (43.5)
>2 cm ≤5 cm 94 (51.9) 95 (51.1)
>5 cm 23 (12.7) 10 (5.4)
Pathological grading 21.354 0.0001*
I 4 (2.9) 19 (12.1)
II 97 (69.3) 122 (77.7)
III 39 (27.9) 16 (10.2)
PTNM 18.290 0.0001*
0~I 32 (17.7) 59 (31.7)
II 89 (49.2) 97 (52.2)
III 60 (33.1) 30 (16.1)
Axillary lymph node metastasis 18.707 0.0001*
yes 106 (58.6) 67 (36.0)
No 75 (41.4) 119 (64.0)
Axillary lymph node 20.801 0.0001*
Transferring positive number
0 75 (41.4) 119 (64.0)
1~3 47 (26.0) 37 (19.9)
4~9 28 (15.5) 16 (8.6)
≥10 31 (17.1) 14 (7.5)
Note: *, P < 0.05.Immunohistochemical results
The positive protein expression rates of ER, PR, C-
erbB2, BRCA1, and WWOX and the high proliferative
rate of Ki67 in the young group were as follows: 66.4%
(71/107), 54.2% (58/107), 27.1% (29/107), 65.4% (70/
107), 86.9% (93/107) and 59.8% (64/107). The positive
protein expression rates of ER, PR, C-erbB2, BRCA1 and
WWOX and the high proliferative rate of Ki67 in the
older group were as follows: 72.3% (81/112), 40.2% (45/
112), 17.0% (19/112), 35.7% (40/112), 86.6% (97/112),
and 55.4% (62/112). The Χ2 test results showed that the
BRCA1 protein expression has statistically significant
differences between the two groups (P < 0.01). The posi-
tive expression rate of BRCA1 protein in the younger
group was higher than that in the older group (Table 2).
Both of the expression sites of the two groups are in the++ 38 (35.5) 10 (8.9)
+++ 19 (17.8) 0 (0)
WWOX 4.610 0.203
— 14 (13.1) 15 (13.4)
+ 56 (52.3) 56 (50.0)
++ 32 (29.9) 27 (24.1)
+++ 5 (4.7) 14 (12.5)
ER 3.867 0.276
— 36 (33.6) 31 (27.7)
+ 48 (44.9) 48 (42.9)
++ 16 (15.0) 28 (25.0)
+++ 7 (6.5) 5 (4.5)
PR 5.215 0.157
— 49 (45.8) 67 (59.8)
+ 48 (44.9) 34 (30.4)
++ 7 (6.5) 7 (6.2)
+++ 3 (2.8) 4 (3.6)
C-erbB2 4.012 0.235
— 63 (58.9) 81 (72.3)
+ 15 (14.0) 12 (10.7)
++ 18 (16.8) 9 (8.1)
+++ 11 (10.3) 10 (8.9)
Ki67 2.128 0.546
<15% 43 (40.2) 50 (44.6)
≥15% 64 (59.8) 52 (55.4)
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sion and Ki67 high proliferation rate had no significant
differences between the two groups (P > 0.05). The
immunohistochemical pictures of ER and PR, HER2,
Ki67, BRCA1 and WWOX protein expression of the
young group and the old group are shown in Figure 2.
Correlation analysis of patient’s parameters
BRCA1 expression was positively correlated with PTNM
stages (r = 0.158, P < 0.05), positively correlated to Axil-
lary lymph node metastasis (r = 0.202, P < 0.01),
(Table 3) and has no correlation with ER, PR, HER2, and
WWOX expression, Ki67 proliferation rate and the
histological grade (P > 0.05). The WWOX expression
has no correlation with various clinical indicators (P >
0.05) (Table 4).
To amplify the BRCA1 gene 2 and 20 exon, we per-
formed PCR using two pairs of sense and antisense
oligonucleotide nucleotide primers. The amplification
results showed that both of them showed single bands
(Figure 3).Figure 2 A (young group) BRCA1 protein immunohistochemical stain
(× 400). B (young group) BRCA1 protein immunohistochemical staining wa
C (old group) BRCA1 protein immunohistochemical staining was positive. T
group) WWOX protein immunohistochemical staining was positive. The po
WWOX protein immunohistochemical staining was positive. The positive p
immunohistochemical staining was positive. The positive product positioni
immunohistochemical staining of PR proteins. The positive products localiz
immunohistochemical staining was positive. The positive products localized
immunohistochemical staining was positive. The positive products localizedDNA sequencing results
The BRCA1 gene has 22 coding exons. We carried out
DNA sequencing around the gene mutation hot spots:
exon 2 and exon 20 in BRCA 1 gene. The exon 2 is 259
bp and the exon 20 is 401 bp, which account for 11.8%
of the total sequence length in exon (660/5600). Se-
quence comparison by the DNAStar and single nucleo-
tide polymorphism (SNP) sites searching method
showed no sequence variation. The partial DNA sequen-
cing results of exon 2 and exon 20 of BRCA1 gene of pa-
tient 6 was shown in Figure 4.
Discussion
Suris-Swarm [5] reported that women younger than 50-
year-old suffering from 4.3 times higher the possibility
of getting bilateral primary breast cancer (BPBC) than
women over the age of 50 year old. Award reported that
women less than 40-year-old are in the population ha-
ving a high risk of getting BPBC [6]. Among the patients
studied in this paper, the diseased tissues are more fre-
quently found in left breasts than the right breasts ofing was positive. The positive products localized in the cytoplasm
s positive. The positive products localized in the nucleus (× 400).
he positive products localized in the cytoplasm (× 400). D (young
sitive products localized in the cytoplasm (× 400). E (old group)
roducts localized in the cytoplasm (× 400). F (young group) ER protein
ng in the nucleus (× 400). G (young group) positive
ed in the nucleus (× 400) H (young group) C-erbB2 protein
in the membrane (× 400). I (young group) Ki67 protein
in the nucleus (× 400).
Table 3 Analysis of the correlation between the BRCA1
results and clinicopathological parameters in the young








— + — +
ER 0.042 0.540
— 13 23 21 10
+ 24 47 51 30
PR 0.073 0.282
— 20 29 42 25
+ 17 41 30 15
C-erbB2 0.051 0.452
— 29 49 59 34
+ 8 21 13 6
Ki67 0.074 0.272
<15% 12 31 29 21
≥15% 25 39 43 19
WWOX −0.145 0.128
— 6 8 7 8
+ 31 62 65 32
Histological grades 0.077 0.260
I 2 1 10 9
II 26 43 53 28
III 9 26 9 3
PTNM 0.158 0.020 *
0~I 5 9 25 11
II 21 34 38 21
III 11 27 9 8
Axillary lymph node metastasis 0.205 0.002*
Yes 23 48 22 18
No 14 22 50 22
Note: *, P < 0.05.
Table 4 Analysis of the correlation between the WWOX
results and clinicopathological parameters in the young








— + — +
ER 0.118 0.080
— 2 34 5 26
+ 12 59 10 71
PR 0.113 0.094
— 6 43 11 56
+ 8 50 4 41
C-erbB2 0.033 0.629
— 11 67 14 79
+ 3 26 1 18
Ki67 0.010 0.987
<15% 6 37 11 4
≥15% 8 56 39 58
Histological grades 0.016 0.819
I 1 2 4 15
II 11 58 11 70
III 2 33 0 12
PTNM −0.085 0.207
0~I 1 13 3 33
II 8 47 10 49
III 5 33 2 15
Axillary lymph node metastasis 0.099 0.144
Yes 12 59 8 32
No 2 34 7 65
Figure 3 A The PCR product of exon 2 of the BRCA1 gene (259
bp). B The PCR product of exon 20 of the BRCA1 gene (401 bp).
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tumors on both of the left and right breasts in the young
group, while no patient get tumors on both of the left
and right breasts in the older group. The majority of
patients have their incidence positions at the outer
upper quadrant, followed by the inner upper quadrant
and the nipple. Triple-negative breast cancer (TNBC)
represents the major phenotype of basal-like molecular
subtype of breast cancer, characterized by higher inci-
dence in young women and a very poor prognosis. Svo-
boda [7] found that expression of miR-34b negatively
correlates with an overall survival of TNBC patients.
Hutter [8] found that the number of lymph node me-
tastasis is one of the decisive factors affecting the prog-
nosis of breast cancer. Patients without lymph node
metastasis have more favorable prognosis than thosehaving lymph node metastasis. The more the number of
metastatic lymph nodes, the worse the prognosis. Xu [9]
found that claudin-6 is an important factor influencing
lymphatic metastasis, whereas up-regulation of HDAC1
is associated with tumor progression and invasiveness in
breast IDC. According to Liu et al. [10], the 3-year -and
Figure 4 A The partial DNA sequencing results of exon 2 of BRCA1 gene of patient 6. B The partial DNA sequencing results of exon 20 of
BRCA1 gene of patient 6.
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lymph node metastasis was 61.11%, 25% and the 3-year
and 5-year survival rates of young breast cancer patients
without lymph node metastasis was 100% and 83.33%,
respectively. It is reported that young breast cancer
patients have higher lymph node metastasis rates. More
lesions are located in the internal mammary areas and
the patients have late clinical stage, higher rate of infil-
trating tumor occurrence, strong tumor invasiveness,
easy transfer, and poor prognosis [11,12]. According to
our research, the younger group has more cases with
tumor diameter greater than 5 cm than the older group
(P < 0.05). The young group has more histological grade
III tumors than the older group (P < 0.01),which is con-
sistent with finding reported by Jimor [13] and Chen
[14]. Since the pathological stage is a judgment made
after visual inspection of the postoperative pathological
specimens, and can more accurately reflect the severity
and extent of breast cancer, it is more accurate than
clinical staging.
In this study, according to the PTNM staging, the
young group has less patients in phases 0 - I and phase
II than the older group, and the numbers of patients in
phase III was significantly more than the elderly group.
Two groups have a significant statistical difference (P <
0.01). The younger group has higher axillary lymph node
metastasis rates and the proportion of positive lymph
node was significantly higher than the older group (P <
0.01), which is consistent with previous reports. In this
study, we found young women with breast cancer have
larger tumor mass, higher histological grade and lymph
node metastasis rate than the elderly group. The major-
ity of patients fall into the PTNM stage III.
As a tumor suppressor gene, the breast cancer suscep-
tibility gene l (BRCA 1), not only inhibits cell growth,
but is also involved in cell cycle regulation, gene tran-
scription, DNA damage repair and apoptosis, and some
other important cellular activities. It plays an important
role in maintaining genetic stability. There is study
found that the BRCA1 protein exits in the nucleus of
normal mammary epithelial cell and the cytoplasm of
tumor cells [15]. Chen et al. [16] find that dislocation ofthe cytoplasmic BRCA1 protein in breast cancer cells is
related to the occurrence and metastasis of breast can-
cer, but the molecular mechanism is unclear. Fu [17]
and Liu [18] found the BRCA1 protein is highly
expressed in breast cancer, suggesting that the abnormal
expression of the BRCA1 has some correlations with the
occurrence and growth of breast cancer. Liu [18] also
found BRCA1 protein expression and the patient age
were negatively correlated. Younger patients have higher
BRCA1 protein expression rate. In our study, BRCA1
protein is expressed in the cytoplasm of breast cancer
cells of both of the young group and elderly group. The
young group has higher positive expression rate than the
old age group (< 0.01). BRCA1 protein expression is
positively correlated with PTNM stage and axillary
lymph node metastasis, which is consistent with the
results reported by Chen [16] and Liu [18]. The younger
group has a higher degree of malignancy and poor prog-
nosis. The ectopic expression of BRCA1 in breast cancer
is closely related to the happening, development and
prognosis of young breast cancer patients.
Tomasz [19] found that methylation of the BRCA1
gene in PB DNA correlates with increased risk of breast
cancer, suggesting that aberrant methylation of genes in
PB and disease predisposition are related. Lv [20]
observed that EGFR gene mutations were rare in breast
carcinomas, but EGFR gene amplification was detected
in about one third of the cases in this population. In
their study, rare mutations in the EGFR gene in patients
with breast cancer were detected, indicating that EGFR
gene mutations are infrequent in this cohort of breast
cancers. We carried out DNA sequencing on the gene
mutation hot spots, the exon 2 and exon 20, in BRCA 1
gene. Fresh specimens of 10 cases of unrelated young in-
vasive ductal carcinoma was compared by DNA sequen-
cing to search for single nucleotide polymorphism (SNP)
sites, the results found no sequence variation.
WWOX protein contains 414 amino acids. In its
amino-terminal, there are two WW domains. The WW
functional domains are related to the interaction be-
tween the proteins [21]. Protein interactions are neces-
sary for the tumor suppressor genes to inhibit tumor
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tion and mutation of WWOX may inhibit apoptosis and
promote tumor occurrence and development [22]. In
this study, WWOX protein expression of the young
group and old group were 86.9% and 86.6%, respectively.
The difference was not statistically significant (P > 0.05),
the experiments also showed no correlation (P > 0.05)
between WWOX and age and other clinical indicators.
Patient age itself is not a major factor affecting the
prognosis of breast cancer. In young patients with poor
prognosis, it is mainly due to their adverse pathological
parameters and invasive biological characteristics.
Therefore, clinically, comprehensive analysis should be
carried on age and tumor clinicopathological and bio-
logical indicators.
Conclusions
The ectopic expression of BRCA1 is associated with the
genesis, progression, and prognosis of young breast can-
cer patients.
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